Strategic Partnerships

Corporate partnerships are another component of Ambit’s strategy to discover and develop best-in-class kinase inhibitors for the treatment of cancer and other diseases. Ambit’s partnering strategy has three distinct components to maximize the value of its discovery capabilities and development assets:

  • Oncology products. We seek to retain rights through discovery and early clinical development, and partner upon demonstrating clinical proof of concept.
  • Non-oncology products. We seek to partner in preclinical or early clinical development.
  • Collaborative research. Through strategic collaborations, we apply our accelerated approach to kinase drug discovery and our proprietary know-how to help partners maximize the value of their kinase-focused small molecule libraries.

For further information on partnering with Ambit on our development-stage projects, or strategic research partnerships, please contact [email protected]